A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515

Alison T. Stopeck, Joseph M. Unger, Lisa M. Rimsza, Michael LeBlanc, Brent Farnsworth, Maria Iannone, Martha J. Glenn, Richard I. Fisher, Thomas P. Miller

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds